Nasal spray COVID treatment trial halted early
Disease control
Terminated
This study tested a nasal spray called AD17002 in adults aged 18 to 65 with mild to moderate COVID-19. Participants received standard care plus either a placebo or one of two doses of the spray. The goal was to see if the spray could help people feel better faster. The trial was …
Phase: PHASE2, PHASE3 • Sponsor: Advagene Biopharma Co. Ltd. • Aim: Disease control
Last updated May 17, 2026 03:54 UTC